MA47415A - Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine - Google Patents

Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine

Info

Publication number
MA47415A
MA47415A MA047415A MA47415A MA47415A MA 47415 A MA47415 A MA 47415A MA 047415 A MA047415 A MA 047415A MA 47415 A MA47415 A MA 47415A MA 47415 A MA47415 A MA 47415A
Authority
MA
Morocco
Prior art keywords
inhibition
platelet aggregation
human gpvi
gpvi antibodies
antibodies
Prior art date
Application number
MA047415A
Other languages
English (en)
Inventor
Gilles Avenard
Philippe Billiald
Martine Jandrot-Perrus
Original Assignee
Acticor Biotech
Inserm Institut National De La Sante Et De La Recherche Scient
Univ Paris Diderot Paris 7
Univ Paris Sud 11
Univ Paris Xiii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acticor Biotech, Inserm Institut National De La Sante Et De La Recherche Scient, Univ Paris Diderot Paris 7, Univ Paris Sud 11, Univ Paris Xiii filed Critical Acticor Biotech
Publication of MA47415A publication Critical patent/MA47415A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
MA047415A 2017-02-03 2018-02-02 Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine MA47415A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17154658 2017-02-03

Publications (1)

Publication Number Publication Date
MA47415A true MA47415A (fr) 2019-12-11

Family

ID=57963133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047415A MA47415A (fr) 2017-02-03 2018-02-02 Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine

Country Status (13)

Country Link
US (2) US11692033B2 (fr)
EP (1) EP3577136A1 (fr)
JP (2) JP7360945B2 (fr)
KR (2) KR102633644B1 (fr)
AU (2) AU2018214222C1 (fr)
BR (1) BR112019016065A8 (fr)
CA (1) CA3051169A1 (fr)
IL (1) IL268299A (fr)
MA (1) MA47415A (fr)
MX (1) MX2019009137A (fr)
SG (1) SG11201906530TA (fr)
TW (2) TW202339799A (fr)
WO (1) WO2018141909A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250026A1 (fr) * 2020-06-08 2021-12-16 Acticor Biotech Utilisation d'anticorps anti-gpvi pour le traitement du syndrome de détresse respiratoire aiguë
WO2023036815A1 (fr) * 2021-09-07 2023-03-16 Etablissement Francais Du Sang Régulation ciblée de l'activation plaquettaire et mégacaryocytaire par co-regroupement d'hétérorécepteurs
WO2023156683A1 (fr) * 2022-02-21 2023-08-24 Acticor Biotech Traitement de maladies cardiovasculaires au moyen d'anticorps anti-gpvi humaine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IE69054B1 (en) 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
DE3903581A1 (de) 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (fr) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Utilisation de JAQ1 (anticorps monoclonal anti-GPVI) en tant que médicament actif pour la protection contre les maladies thrombotiques
EP1406929A2 (fr) 2001-07-18 2004-04-14 MERCK PATENT GmbH Proteines de fusion glycoproteine vi
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1538165A1 (fr) 2003-12-03 2005-06-08 Procorde GmbH Inhibiteurs de la glycoprotéine VI construits à partir de l'anticorps monoclonal hgp 5c4
CN1964990B (zh) 2004-04-29 2012-12-12 大冢制药株式会社 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法
CA2606450A1 (fr) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoproteine vi de membrane plaquettaire
WO2006117910A1 (fr) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
EP1916259A1 (fr) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fragment SCFV anti-gycoprotéine VI pour le traitement de la thrombose
JP5843783B2 (ja) 2009-12-18 2016-01-13 サノフイ ＧＰＶＩに対する新規アンタゴニスト抗体および該抗体のＦａｂフラグメントならびにこれらの使用
JP5989096B2 (ja) 2011-09-01 2016-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトｘｃｒ１抗体
ES2823998T3 (es) 2011-09-08 2021-05-11 Inst Nat Sante Rech Med Nuevos activadores de plasminógeno tisular mutados y usos de los mismos
IL257323B2 (en) 2015-08-05 2024-01-01 Acticor Biotech New antibodies against human GPVI and their uses

Also Published As

Publication number Publication date
BR112019016065A8 (pt) 2022-10-18
CA3051169A1 (fr) 2018-08-09
AU2018214222B2 (en) 2021-01-28
KR102633644B1 (ko) 2024-02-05
KR20190121767A (ko) 2019-10-28
WO2018141909A1 (fr) 2018-08-09
AU2018214222A1 (en) 2019-08-01
AU2021202612B2 (en) 2024-03-14
RU2019127768A3 (fr) 2021-05-28
BR112019016065A2 (pt) 2020-05-26
US20190367608A1 (en) 2019-12-05
CN110494447A (zh) 2019-11-22
TW201839009A (zh) 2018-11-01
US20230391869A1 (en) 2023-12-07
JP2023109987A (ja) 2023-08-08
KR20240046168A (ko) 2024-04-08
JP7360945B2 (ja) 2023-10-13
AU2018214222C1 (en) 2021-08-05
JP2020507317A (ja) 2020-03-12
SG11201906530TA (en) 2019-08-27
AU2021202612A1 (en) 2021-05-27
TWI810173B (zh) 2023-08-01
IL268299A (en) 2019-09-26
MX2019009137A (es) 2019-12-19
RU2019127768A (ru) 2021-03-03
US11692033B2 (en) 2023-07-04
EP3577136A1 (fr) 2019-12-11
TW202339799A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA43956A (fr) Constructions d'anticorps bispécifiques d'engagement avec les cellules t
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA53434A (fr) Anticorps anti-tigit
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA52884A (fr) Anticorps anti-il-11
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA53905A (fr) Anticorps stabilisant trem2
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA46851A (fr) NOUVEAU FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAIN
MA53831A (fr) Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA47415A (fr) Inhibition de l'agrégation plaquettaire à l'aide d'anticorps anti-gpvi humaine
MA52152A (fr) Anticorps
MA44236A (fr) Anticorps anti-tgfbêta 2
MA49781A (fr) Expression directe d'anticorps
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
MA52076A (fr) Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1